Utilizing human-derived soluble matrix to augment healing of critical size bone defects

利用人源可溶性基质促进临界尺寸骨缺损的愈合

基本信息

批准号：
9753933
负责人：
Jennifer Elizabeth Hagen
金额：
$ 19.61万
依托单位：
UNIVERSITY OF FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-01 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9753933
关键词：
Allografting Anti-inflammatory Area Autologous Beds Binding Blood Vessels Bone Morphogenetic Proteins Bone Transplantation Calcium Cartilage Cell Adhesion Cell Proliferation Cell physiology Cells Cessation of life Characteristics Clinical Collagen Complex Data Defect Deposition Development Diagnostic radiologic examination Endothelial Cells Environment Event Expenditure Extracellular Matrix Femur Fiber Fracture Growth Factor HIV/TB Healthcare Histology Human Immunohistochemistry In Vitro Incubated Infection Intervention Laboratories Lead Malaria Measures Mechanics Mediating Mesenchymal Differentiation Mesenchymal Stem Cells Metabolic Methods Minerals Modeling Monitor Morphology Musculoskeletal Nodule Operative Surgical Procedures Orthopedics Osteoblasts Osteogenesis Patients Periosteum Phenotype Physiologic calcification Physiological Process Property Publishing Rattus Research Soft Tissue Injuries Structure Surgeon Techniques Testing Time Tissues Torsion Trauma Umbilical vein Vascular Endothelial Growth Factors Vascular blood supply Vascularization Weight-Bearing state Work Wound Healing angiogenesis angiogenin bone bone healing bone loss bone morphogenetic protein 2 cost demineralization density disability healing human stem cells improved in vivo in vivo evaluation long bone microCT mineralization neonatal human nonhuman tissue novel osteoblast differentiation osteogenic reconstitution reconstruction response scaffold side effect soft tissue standard of care success three dimensional cell culture wound

项目摘要

ABSTRACT Trauma or infection that results in segmental bone loss poses a common, difficult reconstruction dilemma for orthopedic surgeons. Devascularized bone does not heal and is prone to infection. Clinically, it is well established that both an angiogenic and osteogenic environment is needed, but traditionally these two processes have been studied in isolation. This has resulted in many treatment options, but no one solution that works in every patient. Human placental tissue has been shown to have both angiogenic and osteogenic capabilities. It is unknown if these properties can successfully augment the mineralization of critical-sized bone defects. Purified human placental-derived matrix (hPM) is rich in growth factors and has been shown to rapidly create morphologically and phenotypically accurate vascular structures in vitro and functional vessels in vivo. We hypothesize that hPM can facilitate angiogenesis on demineralized bone graft, thus enhancing mineralization of defects. We will measure the angiogenic and osteogenic response to hPM in vitro in 3D culture and test healing of a critical sized defect in an in vivo rat femur defect model.

抽象的导致分段骨质流失的创伤或感染构成了常见的，困难的重建困境骨科医生。血管骨无法愈合，容易感染。临床上，它已经建立了需要一个血管生成和成骨环境，但传统上这两个过程是孤立地研究。这导致了许多治疗选择，但是没有一个解决方案可在每个患者中起作用。人胎盘组织已被证明具有血管生成和成骨功能。这是未知的如果这些特性可以成功增强关键尺寸骨缺损的矿化。纯化的人胎盘衍生的矩阵（HPM）具有丰富的生长因子，并且已显示出迅速在形态上创建在体外体外和功能血管上表型准确的血管结构。我们假设HPM 可以促进非矿化骨移植的血管生成，从而增强缺陷的矿化。我们将测量3D培养中对HPM的血管生成和成骨反应，并测试临界大小的愈合体内大鼠股骨缺陷模型中的缺陷。